Edition:
United States

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

145.08USD
26 Jul 2017
Change (% chg)

-- (--)
Prev Close
$145.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
114,520
52-wk High
$149.34
52-wk Low
$95.16

ABMD.OQ

Chart for ABMD.OQ

About

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops,... (more)

Overall

Beta: 0.20
Market Cap(Mil.): $6,392.81
Shares Outstanding(Mil.): 44.06
Dividend: --
Yield (%): --

Financials

  ABMD.OQ Industry Sector
P/E (TTM): 124.88 40.99 16.81
EPS (TTM): 1.16 -- --
ROI: 12.15 8.49 -5.82
ROE: 12.70 13.46 -5.14

BRIEF-New study with Abiomed's Impella 2.5 Heart Pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery

* New study with Abiomed's Impella 2.5® heart pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery Source text for Eikon: Further company coverage:

Jun 30 2017

BRIEF-Abiomed says enrolled first patient in FDA approved prospective feasibility study

* Abiomed - enrollment of first patient in fda approved prospective feasibility study, STEMI door to unloading with Impella CP system in acute myocardial infarction

May 04 2017

BRIEF-Abiomed Q4 gaap earnings per share $0.33

* Abiomed announces Q4 fy 2017 revenue of $124.7 million, up 33% over prior year and total year revenue of $445.3 million, up 35% over prior year

May 04 2017

BRIEF-Abiomed announces Q4 revenue of $124.7 million, up 33 pct

* Abiomed announces q4 fy 2017 revenue of $124.7 million, up 33% over prior year and total year revenue of $445.3 million, up 35% over prior year

May 04 2017

Earnings vs. Estimates